CN112444497A - Method for detecting dobutamine hydrochloride content - Google Patents
Method for detecting dobutamine hydrochloride content Download PDFInfo
- Publication number
- CN112444497A CN112444497A CN202011148329.4A CN202011148329A CN112444497A CN 112444497 A CN112444497 A CN 112444497A CN 202011148329 A CN202011148329 A CN 202011148329A CN 112444497 A CN112444497 A CN 112444497A
- Authority
- CN
- China
- Prior art keywords
- sample
- solution
- dobutamine hydrochloride
- content
- absorbance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 title claims abstract description 82
- 229960001654 dobutamine hydrochloride Drugs 0.000 title claims abstract description 82
- 238000000034 method Methods 0.000 title claims abstract description 19
- 238000001514 detection method Methods 0.000 claims abstract description 43
- 238000002835 absorbance Methods 0.000 claims abstract description 30
- 239000013558 reference substance Substances 0.000 claims abstract description 28
- 238000000870 ultraviolet spectroscopy Methods 0.000 claims abstract description 13
- 239000000523 sample Substances 0.000 claims description 65
- 239000000243 solution Substances 0.000 claims description 44
- 239000012488 sample solution Substances 0.000 claims description 43
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 36
- 238000002347 injection Methods 0.000 claims description 25
- 239000007924 injection Substances 0.000 claims description 25
- 239000012088 reference solution Substances 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 11
- 238000010790 dilution Methods 0.000 claims description 8
- 239000012895 dilution Substances 0.000 claims description 8
- 238000004364 calculation method Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 238000012937 correction Methods 0.000 claims description 4
- 238000003556 assay Methods 0.000 claims description 3
- 238000010812 external standard method Methods 0.000 claims description 3
- CTENFNNZBMHDDG-UHFFFAOYSA-N Dopamine hydrochloride Chemical compound Cl.NCCC1=CC=C(O)C(O)=C1 CTENFNNZBMHDDG-UHFFFAOYSA-N 0.000 claims 3
- 229960001149 dopamine hydrochloride Drugs 0.000 claims 3
- 239000007858 starting material Substances 0.000 claims 1
- 238000010998 test method Methods 0.000 claims 1
- 238000005259 measurement Methods 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 description 15
- 239000000543 intermediate Substances 0.000 description 13
- 239000002994 raw material Substances 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 230000003044 adaptive effect Effects 0.000 description 5
- 238000011056 performance test Methods 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- -1 1-methyl-3- (4-hydroxyphenyl) propyl Chemical group 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- AUALQMFGWLZREY-UHFFFAOYSA-N acetonitrile;methanol Chemical group OC.CC#N AUALQMFGWLZREY-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- VWMVAQHMFFZQGD-UHFFFAOYSA-N p-Hydroxybenzyl acetone Natural products CC(=O)CC1=CC=C(O)C=C1 VWMVAQHMFFZQGD-UHFFFAOYSA-N 0.000 description 1
- NJGBTKGETPDVIK-UHFFFAOYSA-N raspberry ketone Chemical compound CC(=O)CCC1=CC=C(O)C=C1 NJGBTKGETPDVIK-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- HRQDCDQDOPSGBR-UHFFFAOYSA-M sodium;octane-1-sulfonate Chemical compound [Na+].CCCCCCCCS([O-])(=O)=O HRQDCDQDOPSGBR-UHFFFAOYSA-M 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/33—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/38—Diluting, dispersing or mixing samples
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
The invention provides a method for detecting the content of dobutamine hydrochloride, which adopts an ultraviolet-visible spectrophotometry method, and specifically, the method comprises the steps of comparing the absorbance of a reference substance with known concentration in a specific wavelength range with the absorbance of a sample, and calculating to obtain the content of dobutamine hydrochloride in the sample. The detection method provided by the invention can shorten the detection time, and has the advantages of high measurement accuracy, good stability, good repeatability and good durability.
Description
Technical Field
The invention relates to the technical field of substance detection, and relates to a method for detecting the content of dobutamine hydrochloride.
Background
Dobutamine Hydrochloride (Dobutamine Hydrochloride) with chemical name of 4- [2- [ [ 1-methyl-3- (4-hydroxyphenyl) propyl group]Amino group]Ethyl radical]-1, 2-benzenediol hydrochloride having a molecular formula of C18H23NO3HCl, a synthetic catecholamine drug, which acts directly on the adrenal β receptor, with a smooth action, with significant impact on the heart; dobutamine hydrochloride injection widely used for organic heart diseaseHeart failure, myocardial infarction and cardiac surgery.
In the production process of dobutamine hydrochloride injection, dobutamine hydrochloride raw materials, injection intermediates and injection need to detect the content of dobutamine hydrochloride, at present, the detection method for the content of dobutamine hydrochloride generally adopts a high performance liquid chromatography, and the main steps are as follows: (1) adjusting the wavelength to 280nm, preparing a mobile phase by using octadecylsilane chemically bonded silica as a filler in a chromatographic column, wherein the sample volume is 20 mu L; (2) preparing a sample: taking 1mL of dobutamine hydrochloride injection, and adding a mobile phase to dilute to 0.5 mg/mL; preparing a reference substance and a system adaptive solution by the same method; (3) respectively sampling a system adaptive solution, a reference substance solution and a sample solution, and recording the separation degree of the system adaptive solution and the reference substance and the peak areas of the reference substance and the sample; (4) after the degree of separation is greater than 1.5, the formula is adopted: the concentration of the control, the area of the peak of the sample, the dilution factor of the sample and the area of the peak of the control are used to calculate the content of the sample.
Because the content of the dobutamine hydrochloride needs to be determined in the subsequent production, when the high performance liquid chromatography is used for detecting the content of the dobutamine hydrochloride in the injection intermediate, the detection time of the high performance liquid chromatography is longer, which is equivalent to prolonging the production period and increasing the production cost, and meanwhile, the detection time is overlong, and the content of other sampled products is easy to deviate due to overlong standing time.
Therefore, it is desirable to provide a simple and fast detection method.
Disclosure of Invention
The invention aims to provide a method for detecting the content of dobutamine hydrochloride. The detection method provided by the invention can shorten the detection time, and has the advantages of good stability, good repeatability and good durability.
In order to achieve the purpose, the invention adopts the following technical scheme:
the invention provides a method for detecting the content of dobutamine hydrochloride, which adopts an ultraviolet-visible spectrophotometry.
Specifically, the detection method comprises the following steps: and comparing the absorbance of the reference substance with known concentration in a specific wavelength range with the absorbance of the sample, and calculating to obtain the content of the dobutamine hydrochloride in the sample.
The dobutamine hydrochloride has a certain absorbance in a specific range of an ultraviolet-visible spectrophotometer, and the concentration of the dobutamine hydrochloride and the absorbance form a certain linear relation, so that the content of the dobutamine hydrochloride in a sample can be calculated by an external standard method by utilizing the absorbance of a reference solution.
The invention preferably selects the reference substance of the China pharmaceutical biological product institute for reference, thereby ensuring the accuracy of sample measurement.
As a preferred technical solution of the present invention, the detection method includes the steps of:
(1) detecting the reference solution and the sample solution respectively by using an ultraviolet-visible spectrophotometer to determine the absorbance;
(2) and calculating the content of the dobutamine hydrochloride in the sample solution by using an external standard method.
The calculation method in the step (2) of the invention comprises the following steps:
wherein, C2Is the concentration of dobutamine hydrochloride in the sample solution, mu g/mL; c is the concentration of the reference solution, mu g/mL; a is the absorbance of the reference solution; a. the1Is the absorbance of the sample solution.
To further ensure that the concentration and absorbance are linear, the concentration of the control solution and the concentration of the sample solution are preferably selected from 25-50. mu.g/mL, such as 30. mu.g/mL, 35. mu.g/mL, 40. mu.g/mL, 45. mu.g/mL, etc., independently. In the range, the correlation coefficient of the linear equation is more than 99.9%.
In order to improve the detection sensitivity and the detection accuracy, the invention preferably measures the absorbance of the dobutamine hydrochloride at the maximum absorption position, and the detection wavelength of the ultraviolet-visible spectrophotometer is 276-280nm, preferably 278 nm.
The solvents of the control solution and the sample solution are 0.8-1.0% hydrochloric acid solution, preferably 0.9% hydrochloric acid solution.
The concentration of solvent used in the sample solution and the control solution should be the same.
In order to make the result more accurate, the detection method further comprises the step (1') before the step (1): the uv-vis spectrophotometer is blank calibrated with 0.8-1.0% hydrochloric acid solution, preferably 0.9% hydrochloric acid solution.
The solvent concentration for blank correction according to the present invention should be the same as the solvent concentration used for the sample solution.
After the content of the dobutamine hydrochloride in the sample solution is obtained, the content of the dobutamine hydrochloride in the sample solution also needs to be calculated, and the detection method further comprises the following steps:
and when the sample is liquid, multiplying the content of the dobutamine hydrochloride in the sample solution by the dilution times of the sample solution prepared from the sample to obtain the content of the dobutamine hydrochloride in the sample.
In order to ensure the detection accuracy, the sample needs to be diluted to the concentration of about 30-50 mug/mL, so the concentration of the dobutamine hydrochloride in the sample can be obtained by multiplying the dilution factor after the concentration of the dobutamine hydrochloride in the sample solution is calculated.
And when the sample is solid, multiplying the content of the dobutamine hydrochloride in the sample solution by the volume of the solvent to obtain the content of the dobutamine hydrochloride in the sample.
When the sample is solid, the sample needs to be dissolved to obtain a sample solution, so the final calculation result needs to be multiplied by the volume of the solvent used for dissolving the sample to obtain the content of the dobutamine hydrochloride in the sample.
As a specific embodiment of the present invention, the detection method includes the steps of:
(1) dissolving a reference substance in 0.9% hydrochloric acid solution to obtain a reference substance solution with the concentration of 30-50 mug/mL;
(2) dissolving a sample containing dobutamine hydrochloride in a 0.9% hydrochloric acid solution to obtain a sample solution with the concentration of 25-50 mug/mL;
(3) adjusting the detection wavelength of an ultraviolet-visible spectrophotometer to 278nm, and performing blank correction by using a 0.9% hydrochloric acid solution;
(4) detecting the reference substance solution and the sample solution by using an ultraviolet-visible spectrophotometer with the detection wavelength of 278nm, and measuring the absorbance;
(5) calculating the content of dobutamine hydrochloride in the sample by using the following formula;
wherein, when the sample is liquid, the calculation formula is as follows:
C2the content of dobutamine hydrochloride in the sample is [ mu ] g/mL; c is the concentration of the reference solution, mu g/mL; a is the absorbance of the reference solution; a. the1Is the absorbance of the sample solution; b is1Is the dilution factor when preparing the sample solution from the sample;
when the sample is solid, the calculation formula is:
w1is the percentage content of dobutamine hydrochloride in the sample,%; c is the concentration of the reference solution, mu g/mL; a is the absorbance of the reference solution; a. the1Is the absorbance of the sample solution; l is1Volume of solvent used for sample solution, mL; m is the mass of the sample, μ g.
The detection method provided by the invention can be used for detecting any sample containing dobutamine hydrochloride, and preferably is applied to detecting raw materials, prepared intermediates or products and the like used in the preparation process of the dobutamine hydrochloride injection, wherein the sample comprises the dobutamine hydrochloride raw material, the dobutamine hydrochloride injection intermediate or the dobutamine hydrochloride injection.
The dobutamine hydrochloride raw material is used for preparing the dobutamine hydrochloride injection, and the adopted dobutamine hydrochloride raw material has good purity, but still has trace impurities, so that the dobutamine hydrochloride raw material also needs to be detected.
Compared with the prior art, the invention has the following beneficial effects:
the detection method provided by the invention can shorten the detection time, and has the advantages of high measurement accuracy, good stability, good repeatability and good durability.
Detailed Description
The following examples are intended to illustrate the invention but are not intended to limit the scope of the invention.
The technical solution of the present invention is further explained by the following embodiments. It should be understood by those skilled in the art that the examples are only for the understanding of the present invention and should not be construed as the specific limitations of the present invention.
Preparation example 1
This preparation provides a method for preparing a control solution.
The reference substance of dopamine-butylene hydrochloride (the source is China pharmaceutical biological products institute, lot number 101185-201202) is precisely weighed and dissolved in 0.9 percent hydrochloric acid solution to prepare the reference substance solution with the concentration of 40 mu g/mL.
Preparation examples 2 to 5
This preparation provides a method for preparing a control solution. The difference from preparation example 1 was that the concentrations of the control solutions were 25. mu.g/mL (preparation example 2), 50. mu.g/mL (preparation example 3), 20. mu.g/mL (preparation example 4), and 100. mu.g/mL (preparation example 5).
Example 1
The embodiment provides a method for detecting the content of dobutamine hydrochloride in a dobutamine hydrochloride injection intermediate.
(1) Precisely weighing the intermediate of the dobutamine hydrochloride injection, and dissolving the intermediate in a 0.9% hydrochloric acid solution to prepare a sample solution with the sample concentration of 40 mug/mL.
(2) Adjusting the wavelength of the ultraviolet-visible spectrophotometer to 278nm, performing blank correction by using a 0.9% hydrochloric acid solution, respectively placing the sample solution and the control solution prepared in the preparation example 1 into the ultraviolet-visible spectrophotometer to detect, measuring the absorbance, repeating the steps once, and calculating the average value of the absorbance;
(3) calculating according to the following formula, taking the intermediate of the dobutamine hydrochloride injection in the same batch to perform repeated experiments, and repeating three groups;
wherein, C2The content of dobutamine hydrochloride in the sample is [ mu ] g/mL; c is the concentration of the reference solution, 40 mug/mL; a is the absorbance of the reference solution; a. the1Is the absorbance of the sample solution; b is1Is the dilution factor when preparing the sample solution from the sample;
the results are shown in Table 1
TABLE 1
The embodiment and the performance test show that the RSD measured three times is 0.6 percent, which shows that the detection method provided by the invention has good precision, stability and repeatability.
Comparative example 1
The comparative example provides a method for detecting the content of dobutamine hydrochloride in a dobutamine hydrochloride injection intermediate by using a high performance liquid chromatography.
(1) Adjusting the detection wavelength of a high performance liquid chromatograph to 280nm, using octadecylsilane chemically bonded silica as a filler in a chromatographic column, using a mobile phase A as a mobile phase, wherein the mobile phase B is 55:45, the mobile phase A is 2.6g of sodium octane sulfonate and is dissolved by adding 1000mL of water, adding 3mL of triethylamine and shaking up, adjusting the pH value to 2.5 by using phosphoric acid, and the mobile phase B is acetonitrile-methanol (18:82), and the sample injection amount is 20 mu L;
(2) preparing a sample: taking 1mL of the intermediate of the dobutamine hydrochloride injection in the same batch as the example 1, and adding a mobile phase to dilute the intermediate to 0.5 mg/mL;
preparing a reference substance: taking a reference substance of the dobutamine hydrochloride, and adding a mobile phase to dilute the reference substance to 0.5mg/mL for use;
system adaptation solution: taking appropriate amount of 4- (4-hydroxyphenyl) -2-butanone reference substance and dobutamine hydrochloride reference substance, and dissolving with mobile phase to obtain mixed solution containing 0.3mg and 0.5mg in each 1 mL;
(3) respectively sampling a system adaptive solution, a reference substance solution and a sample solution, and recording the separation degree of the system adaptive solution and the reference substance and the peak areas of the reference substance and the sample;
(4) after the separation degree is more than 1.5, the sample content is calculated by adopting the formula of the concentration of a reference substance, the peak area of the sample, the dilution factor of the sample and the peak area of the reference substance, wherein the peak area of the sample is 1236.2, the peak area of the reference substance is 1241.2, the concentration of the reference substance is 0.5mg/mL, and the result is 10.04 mg/mL.
As can be seen from the comparison between the embodiment 1 and the comparative example 1, the detection method provided by the invention can accurately detect the content of dobutamine hydrochloride in the sample, and the detection method of the comparative example 1 needs to be completed within 2 hours, while the preparation method of the invention can be completed within 30min from the preparation of the sample to the final detection, so that the detection time is short, the detection method is simple and rapid, the production period is shortened, the production yield is increased, and the production cost is reduced.
Examples 2 to 5
The embodiment provides a method for detecting the content of dobutamine hydrochloride in a dobutamine hydrochloride injection intermediate. The difference from example 1 is that the control solution provided in preparation example 1 was replaced with the control solutions provided in preparation examples 2 to 5, and the sample solutions prepared at the end of step (1) had concentrations of 25. mu.g/mL (example 2), 50. mu.g/mL (example 3), 20. mu.g/mL (example 4), and 100. mu.g/mL (example 5).
The test results are shown in table 2:
TABLE 2
As can be seen from the examples and performance tests, the concentration of the control and sample is preferably in the range of 25-50 μ g/mL, and the concentration is too high or too low, which may cause the test result to have a deviation in a small range.
Example 6
The embodiment provides a method for detecting the content of dobutamine hydrochloride in a dobutamine hydrochloride injection. The difference from example 1 is that the sample in step (1) is dobutamine hydrochloride injection.
The test results are shown in table 3:
TABLE 3
The embodiment and the performance test show that the detection method provided by the invention is also suitable for the dobutamine hydrochloride injection, and has good test stability and good repeatability.
Comparative example 2
The comparative example provides a method for detecting the content of dobutamine hydrochloride in a dobutamine hydrochloride injection by using a high performance liquid chromatography. The difference from comparative example 1 is that the sample in step (2) was replaced with dobutamine hydrochloride injection of the same batch as in example 6.
The assay result was 9.91. mu.g/mL.
As can be seen from the comparison between example 6 and comparative example 2, the detection method provided by the present invention has high accuracy and can be used in place of high performance liquid chromatography.
Example 7
The embodiment provides a method for detecting a dobutamine hydrochloride raw material. The difference from the example 1 is that the sample in the step (1) is dobutamine hydrochloride raw material, and the calculation method in the step (3) is as follows:
w1is the percentage content of dobutamine hydrochloride in the sample,%; c is the concentration of the reference solution, 40 mug/mL; a is the absorbance of the reference solution; a. the1Is the absorbance of the sample solution; l is1Volume of solvent used for sample solution, mL; m is the mass of the sample, 10. mu.g.
The test results are shown in table 4:
TABLE 4
The embodiment and the performance test show that the detection method provided by the invention is also suitable for the dopol butamine hydrochloride raw material, and has good test stability and good repeatability.
Examples 8 to 9
The embodiment provides a method for detecting the content of dobutamine hydrochloride in a dobutamine hydrochloride injection intermediate. The difference from example 1 is that the inspection wavelengths were adjusted to 270nm (example 8) and 290nm (example 9).
The test results are shown in table 5:
TABLE 5
As can be seen from the examples and performance tests, the wavelength of the present invention is preferably in the range of 276-280nm, and deviation of the test results may possibly occur if the wavelength is not in the range.
Although the invention has been described in detail hereinabove by way of general description, specific embodiments and experiments, it will be apparent to those skilled in the art that many modifications and improvements can be made thereto based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.
Claims (10)
1. The method for detecting the content of dobutamine hydrochloride is characterized by adopting an ultraviolet-visible spectrophotometry.
2. The detection method according to claim 1, characterized in that the detection method is: and comparing the absorbance of the reference substance with known concentration in a specific wavelength range with the absorbance of the sample, and calculating to obtain the content of the dobutamine hydrochloride in the sample.
3. The detection method according to claim 2, characterized in that it comprises the steps of:
(1) respectively detecting the sample solution and a reference solution with known concentration by using an ultraviolet-visible spectrophotometer, and determining absorbance;
(2) and calculating the content of the dobutamine hydrochloride in the sample solution by using an external standard method.
4. The assay of claim 3, wherein the concentration of the control solution and the sample solution is independently selected from 25-50 μ g/mL.
5. The detection method according to claim 3 or 4, wherein the detection wavelength of the UV-Vis spectrophotometer is 276 nm and 280nm, preferably 278 nm.
6. The test method according to any one of claims 3 to 5, wherein the solvent of the control solution and the sample solution is 0.8 to 1.0% hydrochloric acid solution, preferably 0.9% hydrochloric acid solution.
7. The detection method according to claim 6, further comprising, before performing step (1), performing step (1'): the uv-vis spectrophotometer is blank calibrated with 0.8-1.0% hydrochloric acid solution, preferably 0.9% hydrochloric acid solution.
8. The detection method according to any one of claims 3-7, further comprising:
when the sample is liquid, multiplying the content of the dobutamine hydrochloride in the sample solution by the dilution times of the sample solution prepared from the sample to obtain the content of the dobutamine hydrochloride in the sample;
and when the sample is solid, multiplying the content of the dobutamine hydrochloride in the sample solution by the volume of the solvent to obtain the content of the dobutamine hydrochloride in the sample.
9. The detection method according to any one of claims 3 to 8, characterized in that it comprises the steps of:
(1) dissolving a reference substance in 0.9% hydrochloric acid solution to obtain a reference substance solution with the concentration of 30-50 mug/mL;
(2) dissolving a sample containing dobutamine hydrochloride in a 0.9% hydrochloric acid solution to obtain a sample solution with the concentration of 25-50 mug/mL;
(3) adjusting the detection wavelength of an ultraviolet-visible spectrophotometer to 278nm, and performing blank correction by using a 0.9% hydrochloric acid solution;
(4) detecting the reference substance solution and the sample solution by using an ultraviolet-visible spectrophotometer with the detection wavelength of 278nm, and measuring the absorbance;
(5) calculating the content of dobutamine hydrochloride in the sample by using the following formula;
wherein, when the sample is liquid, the calculation formula is as follows:
C1is the concentration of dobutamine hydrochloride in the sample, mu g/mL; c is the concentration of the reference solution, mu g/mL; a isAbsorbance of the control solution; a. the1Is the absorbance of the sample solution; b is1Is the dilution factor when preparing the sample solution from the sample;
when the sample is solid, the calculation formula is:
w1is the percentage content of dobutamine hydrochloride in the sample,%; c is the concentration of the reference solution, mu g/mL; a is the absorbance of the reference solution; a. the1Is the absorbance of the sample solution; l is1Volume of solvent used for sample solution, mL; m is the mass of the sample, μ g.
10. The assay of any one of claims 2-9, wherein the sample is selected from a dopamine hydrochloride starting material, a dopamine hydrochloride injection intermediate, or a dopamine hydrochloride injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011148329.4A CN112444497A (en) | 2020-10-23 | 2020-10-23 | Method for detecting dobutamine hydrochloride content |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011148329.4A CN112444497A (en) | 2020-10-23 | 2020-10-23 | Method for detecting dobutamine hydrochloride content |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112444497A true CN112444497A (en) | 2021-03-05 |
Family
ID=74736155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011148329.4A Pending CN112444497A (en) | 2020-10-23 | 2020-10-23 | Method for detecting dobutamine hydrochloride content |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112444497A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6017966A (en) * | 1995-10-27 | 2000-01-25 | Rhone-Poulenc Rorer Sa | Stabilized pharmaceutical compositions containing dobutamine |
| WO2007022255A2 (en) * | 2005-08-15 | 2007-02-22 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained release |
| JP2014155487A (en) * | 2013-01-17 | 2014-08-28 | Toyobo Co Ltd | Biogenic substance measurement method, and composition for measurement |
| CN105675523A (en) * | 2014-11-17 | 2016-06-15 | 蚌埠丰原涂山制药有限公司 | Ambroxol content UV spectrophotometric test method |
| CN109851511A (en) * | 2017-11-30 | 2019-06-07 | 浙江普利药业有限公司 | A kind of synthetic method of dobutamine hydrochloride |
-
2020
- 2020-10-23 CN CN202011148329.4A patent/CN112444497A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6017966A (en) * | 1995-10-27 | 2000-01-25 | Rhone-Poulenc Rorer Sa | Stabilized pharmaceutical compositions containing dobutamine |
| WO2007022255A2 (en) * | 2005-08-15 | 2007-02-22 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained release |
| JP2014155487A (en) * | 2013-01-17 | 2014-08-28 | Toyobo Co Ltd | Biogenic substance measurement method, and composition for measurement |
| CN105675523A (en) * | 2014-11-17 | 2016-06-15 | 蚌埠丰原涂山制药有限公司 | Ambroxol content UV spectrophotometric test method |
| CN109851511A (en) * | 2017-11-30 | 2019-06-07 | 浙江普利药业有限公司 | A kind of synthetic method of dobutamine hydrochloride |
Non-Patent Citations (1)
| Title |
|---|
| 中华人民共和国卫生部药典委员会: "《中华人民共和国药典 1990年版 二部 药典注释》", 31 December 1993, 北京：化学工业出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106248607A (en) | Utilize the method that first derivative ultraviolet spectro-photometry measures oligochitosan deacetylation | |
| Guan et al. | Determination of the enantiomeric impurity in S‐(–) pantoprazole using high performance liquid chromatography with sulfobutylether‐beta‐cyclodextrin as chiral additive | |
| CN109738560B (en) | Method for measuring content of tartaric acid optical isomer | |
| CN112444497A (en) | Method for detecting dobutamine hydrochloride content | |
| Khan et al. | Determination of glimepiride in pharmaceutical formulations using HPLC and first-derivative spectrophotometric methods | |
| CN116626087A (en) | Method for quantitatively analyzing allyl sucrose ether content through nuclear magnetic resonance hydrogen spectrum | |
| CN114563495B (en) | Detection method of acetylcysteine and related substances thereof | |
| CN102875449B (en) | Separation method for tirofiban hydrochloride isomer, and metering method for D-configuration tirofiban hydrochloride | |
| CN114527213A (en) | Quality detection method for topiroxostat | |
| CN110231416B (en) | Method for measuring 2-iodoxybenzoic acid related substances by using HPLC (high performance liquid chromatography) | |
| CN111289653B (en) | Method for detecting 5-hydroxymethylfurfural impurity and impurity I in nicardipine hydrochloride glucose injection | |
| CN114594168A (en) | Method for detecting indobufen impurity | |
| CN109239214B (en) | Method for detecting Shakubiqu isomers in Shakubiqu sodium | |
| CN104897753B (en) | A kind of nano-porous gold silver alloy wire electrode of molecularly imprinted polymer modification and its application | |
| CN111707766A (en) | Detection method of furotriptan succinate tablet | |
| GA et al. | VALIDATED RP-HPLC AND UV-SPECTROSCOPY METHODS FOR THE ESTIMATION OF DAPAGLIFLOZIN IN BULK AND IN TABLETS. | |
| Antakli et al. | Determination of Amoxicillin Trihydrate by Analytical Spectrophotometry | |
| CN113607842A (en) | Method for identifying and measuring content of lactic acid in levofloxacin lactate | |
| Kabaweh et al. | Determination of some bronchodilator and expectorant drugs (guaifenesin and theophylline) using HPLC technique | |
| CN114689767A (en) | Method for detecting aripiprazole raw material and related substances of aripiprazole preparation | |
| CN116754705B (en) | Method for detecting acetic acid and acetate content | |
| Khader et al. | Development and validation of reverse phase HPLC method for simultaneous estimation of allopurinol and lesinurad in its API and pharmaceutical dosage form | |
| CN114295747B (en) | Analysis method of Parami Wei Qishi material and impurities | |
| CN106290620B (en) | A kind of detection method of Afatinib bulk pharmaceutical chemicals isomers | |
| CN116008435B (en) | Method for measuring content of 2, 4-dibromo-5-chlorobenzoic acid by high performance liquid chromatography |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210305 |
|
| RJ01 | Rejection of invention patent application after publication |